Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

episode

CME in Minutes: Education in Primary Care not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

2026-09-24- KSR - Hour 1 1h 4m · 24 Sep 2026 · KSR

Is This The October Surprise? (Ep. 2602) 1h 30m · 24 Sep 2026 · The Dan Bongino Show

Sage Advice From Granny Bingo 19 min · 24 Sep 2026 · It's A Lot with Abbie Chatfield

Trump, Xi Begin State Visit, Oil Soars on Iran Threat, More 7 min · 24 Sep 2026 · Bloomberg News Now

The Single Dumbest Thing Ever Said About the Miami Heat | Hour 2 37 min · 24 Sep 2026 · The Dan Le Batard Show

The Podcast is Pregnant: Thursday, September 24th, 2026 1h 12m · 24 Sep 2026 · The Toast

Report any issue

Source

Recorded05 Sep 2023

Publisherc.answersincme.com ↗

Handlerec:10296344

Show notes

Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in